Anderson Hoagland & Co. Has $1.91 Million Stock Position in Illumina, Inc. $ILMN

Anderson Hoagland & Co. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,555 shares of the life sciences company’s stock after acquiring an additional 6,183 shares during the quarter. Anderson Hoagland & Co.’s holdings in Illumina were worth $1,909,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Quent Capital LLC acquired a new stake in Illumina in the 3rd quarter worth about $29,000. Quarry LP bought a new stake in Illumina in the 3rd quarter valued at about $32,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Illumina during the 3rd quarter worth approximately $33,000. Strategic Advocates LLC acquired a new position in shares of Illumina during the 3rd quarter worth approximately $44,000. Finally, Mather Group LLC. bought a new position in shares of Illumina during the third quarter worth approximately $46,000. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of a number of analyst reports. TD Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. JPMorgan Chase & Co. lowered their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Robert W. Baird set a $137.00 target price on Illumina in a research report on Friday, February 6th. Finally, Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Stock Performance

NASDAQ ILMN opened at $126.59 on Friday. The firm’s 50 day simple moving average is $131.25 and its 200 day simple moving average is $120.45. The firm has a market capitalization of $19.36 billion, a price-to-earnings ratio of 23.23, a P/E/G ratio of 2.35 and a beta of 1.45. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the business earned $0.95 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Expanded Labcorp collaboration to drive NGS adoption, expand distributed testing access, generate evidence for payer coverage and develop new oncology tests—provides a clear commercial growth pathway for Illumina’s oncology sequencing business. Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
• Positive Sentiment: Quarterly / sector commentary highlights Illumina as “firing on all cylinders,” reinforcing that recent earnings and revenue trends support upside in sequencing product and services demand. Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders
• Neutral Sentiment: Analyst fair-value modeling saw only a very small adjustment (from $135.94 to $136.05), signaling modest change to the baseline valuation despite active coverage shifts—mixed views persist across the Street. How The Illumina (ILMN) Story Is Shifting With 2026 Expectations And Mixed Street Views
• Neutral Sentiment: Broader analyst / comparative write-ups and stock-screen coverage (including independent company analyses) are circulating but don’t add a clear directional push—useful for longer-term thesis rather than immediate catalyst. Analyzing Illumina (NASDAQ:ILMN) and CervoMed (NASDAQ:CRVO)
• Negative Sentiment: Some strategists warn that recent share gains may already price in a stronger Q4 and 2026 outlook, which raises the risk of limited near-term upside or a pullback if execution or macro assumptions slip. ILMN Stock Gains Following Expanded Collaboration With Labcorp

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.